Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.22B P/E - EPS this Y 14.40% Ern Qtrly Grth -
Income -205.8M Forward P/E -6.79 EPS next Y 12.30% 50D Avg Chg 8.00%
Sales 262.36M PEG -0.08 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 1.74 EPS next 5Y 150.00% 52W High Chg -64.00%
Recommedations 2.10 Quick Ratio 5.31 Shares Outstanding 57.82M 52W Low Chg 87.00%
Insider Own 1.79% ROA -15.87% Shares Float 56.96M Beta 1.64
Inst Own 113.08% ROE -30.80% Shares Shorted/Prior 12.01M/12.36M Price 21.39
Gross Margin 35.79% Profit Margin -78.44% Avg. Volume 1,268,609 Target Price 40.75
Oper. Margin -65.70% Earnings Date May 3 Volume 1,361,700 Change -6.55%
About Twist Bioscience Corporation

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Corporation News
03/28/24 Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
03/05/24 Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
02/22/24 Twist Bioscience to Present at Upcoming Investor Conferences
02/13/24 7 Stocks Cathie Wood Is Still Loading Up On in Q1
02/10/24 Twist Bioscience Corp Director Robert Chess Sells 4,110 Shares
02/07/24 Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
02/06/24 Twist Bioscience Corporation (NASDAQ:TWST) Analysts Are Pretty Bullish On The Stock After Recent Results
02/06/24 Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
02/06/24 Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
02/05/24 Twist Bioscience Corporation (NASDAQ:TWST) Q1 2024 Earnings Call Transcript
02/05/24 Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
02/02/24 Q1 2024 Twist Bioscience Corp Earnings Call
02/02/24 Twist Bioscience Corp Reports Strong Revenue Growth in Q1 Fiscal 2024
02/02/24 Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results
01/24/24 Twist Bioscience Expands Express Genes Rapid Synthesis Service
01/16/24 Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024
01/08/24 Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
01/05/24 Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
12/19/23 3 Genomics Stocks to Unlock the Future of Medicine
12/18/23 Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference
TWST Chatroom

User Image Stock_Titan Posted - 19 hours ago

$TWST Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations https://www.stocktitan.net/news/TWST/twist-bioscience-launches-pangenome-spike-in-exome-panel-to-enable-x5c78fljf4t3.html

User Image DonCorleone77 Posted - 3 days ago

$TWST Cathie Wood's ARK Investment bought 129K shares of Twist Bioscience today

User Image madnessofcrowds Posted - 1 week ago

$TWST great action but need more volume

User Image StockInvest_us Posted - 1 week ago

Signal alert: $TWST - Oversold Trend Short (Undervalued) https://stockinvest.us/l/keepUR8u5I

User Image AnchorsAweigh Posted - 1 week ago

$TWST didn’t take long for the boner candle to present itself

User Image Plan2TradeTrade2Plan Posted - 1 week ago

$TWST more Cathie purchases today!

User Image AnchorsAweigh Posted - 1 week ago

$TWST Genomics name. Nice R/R here vs Jan low for a higher low dip buy

User Image WantedToRetireEarly Posted - 1 week ago

@jaydilks agree and to be clear I DO want DNA to succeed I never short any stock although I should have shorted FSR at 6 when I sold. But I hate the idea of shorting any company except possibly DWAC😉 And agree with you that the failure of DNA will hit $TWST as they are a major customer.

User Image WantedToRetireEarly Posted - 2 weeks ago

$DNA Wow, about to go sub $1. I'm not surprised and don't say I didn't warn you. $TWST remains the much better play in this space, even if it's not all synth bio.

User Image WantedToRetireEarly Posted - 2 weeks ago

$TWST the stock is actually down 3.5% pre market. Can’t trust ST’s pre market numbers!!

User Image WantedToRetireEarly Posted - 2 weeks ago

$TWST why up big this morning? Any news?

User Image Thelonius_Stonk Posted - 2 weeks ago

$TWST coiled up pretty tight

User Image WantedToRetireEarly Posted - 2 weeks ago

@GrowthOverEverything agree that $TWST is far more investable and has a better business model that has a much better chance of reaching profitability sooner than DNA. Stock price tells the tale. TWST has recovers from a low of 11 to now close to $40. DNA is near all time lows.

User Image Rebooter Posted - 2 weeks ago

@GoldenKnightsFan Pac Bio for sure, I don't follow Guardant. I also like $FATE, $TWST, $BEAM. Generally bullish on the gene editing and oncology segments. A bunch of these companies are at an inflection point with Phase 3 trials etc.

User Image Rakim_Bee Posted - 2 weeks ago

$TWST disappointing action today.

User Image AnchorsAweigh Posted - 2 weeks ago

$TWST turning up

User Image JFDI Posted - 2 weeks ago

$TWST & ...

User Image ElliottwaveForecast Posted - 2 weeks ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/ #Elliottwave #Trading #TWIST

User Image ElliottwaveForecast Posted - 3 weeks ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/… #Elliottwave #Trading #TWIST

User Image TAPlot Posted - 3 weeks ago

Was stopped out breakeven on $twst I don't like it coming back down to the 50 MA after that bounce from 21 EMA but interesting setup. Market still lacks broad participation so hard to press on risk.

User Image ElliottwaveForecast Posted - 3 weeks ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/ #Elliottwave #Trading #TWIST

User Image Stock_Titan Posted - 3 weeks ago

$TWST Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing https://www.stocktitan.net/news/TWST/twist-bioscience-launches-ivdr-compliant-precision-dx-products-for-i9vasdpqreat.html

User Image ElliottwaveForecast Posted - 3 weeks ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/ #Elliottwave #Trading #TWIST

User Image jaydilks Posted - 3 weeks ago

$DNA Would the US Government be better off with a thriving Ginkgo Bioworks or a FAILING Ginkgo Bioworks? What rapid mergers would make DNA better immediately? $TWST would be at the top of my list.

User Image ElliottwaveForecast Posted - 3 weeks ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/ #Elliottwave #Trading #TWIST

User Image WantedToRetireEarly Posted - 3 weeks ago

@VikeInvests same here. First bought it around 3 thinking that was finally the bottom. Wrong! Has been a complete lemon. The only stock in this sector that I bought, lost massively on but then decided to hold has been $TWST. They are growing and have a business model that just might work. This year or next could be their inflection point. Pick and shovel play to the synth bio sector and other bio techs. Recommend researching it. Lovely chart since the lows tells a lot. Rare case where I decided to hold a big loser and it worked out.

User Image ElliottwaveForecast Posted - 4 weeks ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/ #Elliottwave #Trading #TWIST

User Image GrowthOverEverything Posted - 4 weeks ago

$DNA buy $twst instead. jason dropping all kinds of hints at which companies you should buy and which you shouldn't!!!! listen closely

User Image ElliottwaveForecast Posted - 1 month ago

Twist Bioscience Corp (NASDAQ: $TWST) Daily Investment Opportunity https://elliottwave-forecast.com/stock-market/twist-bioscience-twst-investment/ #Elliottwave #Trading #TWIST

User Image WOLFSTREET Posted - 1 month ago

$TWST You waited for 20s and thus, missed the move. Double Tap 32 and off to the races. This was also assuming the gap would fill, but that did not happen, not in this cycle. Lines, lines, and more lines on charts.

Analyst Ratings
Scotiabank Sector Outperform Feb 5, 24
Barclays Overweight Jan 25, 24
Goldman Sachs Buy Jan 18, 24
Goldman Sachs Buy Jan 17, 24
Berenberg Buy Sep 27, 23
Barclays Overweight Aug 7, 23
Goldman Sachs Neutral Jul 13, 23
Baird Outperform May 8, 23
Barclays Overweight May 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Green Paula SVP of Human Resourc.. SVP of Human Resources Sep 16 Option 5.95 8,514 50,658 22,610 09/20/22
Green Paula SVP of Human Resourc.. SVP of Human Resources Sep 16 Sell 37.43 8,514 318,679 14,199 09/20/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Aug 16 Option 11.59 9,000 104,310 47,831 08/18/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 50.06 13,900 695,834 38,831 08/18/22
Banyai William See Remarks See Remarks Jul 22 Sell 43.19 378 16,326 258,729 07/26/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 14 Option 20.53 6,620 135,909 53,308 04/18/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 14 Sell 43.12 6,620 285,454 46,688 04/18/22
Banyai William See Remarks See Remarks Apr 01 Sell 53.61 318 17,048 262,455 04/05/22
Banyai William See Remarks See Remarks Feb 18 Sell 52.66 1,280 67,405 263,073 02/23/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Feb 18 Option 25 3,517 87,925 51,442 02/23/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Feb 18 Sell 52.86 4,442 234,804 47,000 02/23/22
Banyai William See Remarks See Remarks Jan 24 Sell 54.73 348 19,046 265,174 01/26/22
Banyai William See Remarks See Remarks Oct 22 Sell 117.39 19,791 2,323,265 306,378 10/26/21
Leproust Emily M. President & CEO President & CEO Oct 21 Option 5.95 1,740 10,353 174,222 10/25/21
Leproust Emily M. President & CEO President & CEO Oct 21 Sell 120.99 1,740 210,523 172,482 10/25/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer Oct 13 Option 20.17 4,906 98,954 53,902 10/15/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer Oct 13 Sell 104 4,906 510,224 48,996 10/15/21
Banyai William See Remarks See Remarks Oct 13 Option 7.39 28,181 208,258 326,457 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 13 Option 5.95 1,740 10,353 174,222 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 13 Sell 110.16 1,740 191,678 172,482 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 06 Option 5.95 8,700 51,765 174,222 10/08/21
Leproust Emily M. President & CEO President & CEO Oct 06 Sell 99.05 8,700 861,735 172,482 10/08/21
Leproust Emily M. President & CEO President & CEO Sep 13 Sell 118.46 29,587 3,504,876 219,143 09/13/21
Leproust Emily M. President & CEO President & CEO Sep 13 Option 7.39 29,587 218,648 233,063 09/13/21
JOHANNESSEN JAN Director Director Aug 20 Option 14 5,000 70,000 6,898 08/20/21
JOHANNESSEN JAN Director Director Aug 20 Sell 97.11 5,000 485,550 1,898 08/20/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer May 21 Option 20.17 4,905 98,934 57,109 05/21/21
JOHANNESSEN JAN Director Director May 21 Option 14 5,000 70,000 6,898 05/21/21
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 26 Option 11.59 5,000 57,950 53,034 04/26/21
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 26 Sell 133.47 5,000 667,350 48,034 04/26/21
Leproust Emily M. President & CEO President & CEO Apr 15 Sell 128.84 2,000 257,680 265,843 04/15/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Apr 07 Option 19.6 2,702 52,959 45,446 04/07/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Apr 07 Sell 126.72 2,702 342,397 42,744 04/07/21
Daniels Mark See Remarks See Remarks Feb 26 Option 23.33 620 14,465 67,546 02/26/21
Daniels Mark See Remarks See Remarks Feb 26 Sell 134.31 620 83,272 66,926 02/26/21
Banyai William See Remarks See Remarks Feb 24 Sell 144.18 20,275 2,923,250 440,987 02/24/21
Leproust Emily M. President & CEO President & CEO Feb 11 Sell 178.43 75,000 13,382,250 02/11/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Feb 04 Option 19.6 2,702 52,959 46,729 02/04/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Feb 04 Sell 183.59 2,702 496,060 44,027 02/04/21
Daniels Mark See Remarks See Remarks Feb 01 Option 8.82 377 3,325 68,577 02/01/21
Daniels Mark See Remarks See Remarks Feb 01 Sell 161.02 377 60,705 68,200 02/01/21
Green Paula SVP of Human Resourc.. SVP of Human Resources Jan 26 Sell 193 246 47,478 22,250 01/26/21
Daniels Mark See Remarks See Remarks Jan 26 Option 23.33 620 14,465 68,820 01/26/21
Daniels Mark See Remarks See Remarks Jan 26 Sell 193 905 174,665 68,200 01/26/21
Banyai William See Remarks See Remarks Jan 26 Sell 192.95 14,099 2,720,402 461,937 01/26/21
Leproust Emily M. President & CEO President & CEO Jan 19 Sell 182.92 10,000 1,829,200 421,196 01/19/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Jan 07 Option 19.6 2,702 52,959 46,930 01/07/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Jan 07 Sell 132.93 2,702 359,177 44,228 01/07/21
Daniels Mark See Remarks See Remarks Dec 29 Option 16.08 997 16,032 69,164 12/29/20
Daniels Mark See Remarks See Remarks Dec 29 Sell 167.45 997 166,948 68,787 12/29/20